RAF1 and colorectal carcinoma: RAF inhibitors were found to elicit innate resistance via secretion of the growth factor HGF by stromal cells, resulting in ERK and PI3K-AKT activation and therapy resistance [143]; these results suggest a potential for the concurrent application of RAF and HGF/MET inhibitors in CRC and other cancers.